Michael C. Donegan - Dec 6, 2022 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role
Interim CFO/CAO/VP of Finance
Signature
/s/ Michael C. Donegan
Stock symbol
TXMD
Transactions as of
Dec 6, 2022
Transactions value $
-$4,345
Form type
4
Date filed
12/9/2022, 06:37 PM
Previous filing
Mar 31, 2022
Next filing
Jan 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXMD Common Stock Options Exercise $0 +2.3K +115.69% $0.00 4.29K Dec 6, 2022 Direct F1
transaction TXMD Common Stock Options Exercise $0 +380 +8.86% $0.00 4.67K Dec 6, 2022 Direct F1
transaction TXMD Common Stock Options Exercise $0 +534 +11.44% $0.00 5.2K Dec 6, 2022 Direct F1
transaction TXMD Common Stock Options Exercise $0 +262 +5.04% $0.00 5.46K Dec 6, 2022 Direct F1
transaction TXMD Common Stock Sale -$4.35K -910 -16.65% $4.78 4.55K Dec 6, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Restricted Stock Units Options Exercise $0 -2.3K -100% $0.00* 0 Dec 6, 2022 Common Stock 2.3K $0.00 Direct F1, F4
transaction TXMD Restricted Stock Units Options Exercise $0 -380 -50% $0.00 380 Dec 6, 2022 Common Stock 380 $0.00 Direct F1, F5
transaction TXMD Restricted Stock Units Options Exercise $0 -534 -33.38% $0.00 1.07K Dec 6, 2022 Common Stock 534 $0.00 Direct F1, F6
transaction TXMD Restricted Stock Units Options Exercise $0 -262 -33.55% $0.00 519 Dec 6, 2022 Common Stock 262 $0.00 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2 The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.76 and $5.29, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F4 The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022.
F5 The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.
F6 The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.
F7 Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.